Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 44,950 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 44,950 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $20.31, for a total transaction of $912,934.50. Following the completion of the sale, the president directly owned 1,042,110 shares of the company’s stock, valued at $21,165,254.10. This represents a 4.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Arcus Biosciences Price Performance

Shares of NYSE:RCUS opened at $20.25 on Thursday. The company has a market capitalization of $2.19 billion, a P/E ratio of -5.89 and a beta of 0.90. Arcus Biosciences, Inc. has a 1-year low of $6.50 and a 1-year high of $22.11. The firm’s 50 day simple moving average is $16.25 and its two-hundred day simple moving average is $11.81. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 3.65.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.06. The firm had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The company’s revenue was down 45.8% on a year-over-year basis. During the same period last year, the firm earned ($1.00) EPS. Research analysts expect that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Arcus Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of RCUS. Jacobs Levy Equity Management Inc. raised its holdings in Arcus Biosciences by 39.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,120,062 shares of the company’s stock valued at $15,233,000 after buying an additional 314,757 shares during the period. Vestal Point Capital LP bought a new stake in Arcus Biosciences in the third quarter worth about $3,400,000. Public Employees Retirement System of Ohio purchased a new position in shares of Arcus Biosciences during the third quarter valued at approximately $299,000. Parkman Healthcare Partners LLC boosted its position in shares of Arcus Biosciences by 8.9% during the third quarter. Parkman Healthcare Partners LLC now owns 652,680 shares of the company’s stock valued at $8,876,000 after buying an additional 53,070 shares during the period. Finally, Decheng Capital LLC grew its stake in shares of Arcus Biosciences by 242.3% during the third quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock valued at $7,447,000 after buying an additional 387,609 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on RCUS shares. The Goldman Sachs Group boosted their price target on Arcus Biosciences from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. HC Wainwright lifted their price target on shares of Arcus Biosciences from $24.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Truist Financial reiterated a “buy” rating and issued a $39.00 target price (up from $32.00) on shares of Arcus Biosciences in a research report on Tuesday, October 7th. Finally, Wedbush set a $35.00 price target on Arcus Biosciences and gave the company an “outperform” rating in a report on Wednesday, October 29th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Arcus Biosciences has an average rating of “Moderate Buy” and an average price target of $28.44.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.